Lanxess-Aktie an MDax-Spitze: Chemutra-Übernahme treibt an

Erst am Vortag war der Vertrag des Managers vorzeitig um fünf Jahre bis 2024 verlängert worden. Auch bei den Anlegern punktete …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
628